SRR25043630
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.240
- PEROXISOME+0.240
- PROTEIN_SECRETION+0.210
- PANCREAS_BETA_CELLS+0.170
- APICAL_SURFACE+0.160
- XENOBIOTIC_METABOLISM+0.150
- BILE_ACID_METABOLISM+0.140
- KRAS_SIGNALING_DN+0.140
- UV_RESPONSE_DN+0.140
- COAGULATION+0.130
Top 10 suppressed
- E2F_TARGETS-0.570
- MYC_TARGETS_V2-0.560
- G2M_CHECKPOINT-0.520
- MYC_TARGETS_V1-0.520
- MTORC1_SIGNALING-0.420
- TNFA_SIGNALING_VIA_NFKB-0.390
- MITOTIC_SPINDLE-0.380
- PI3K_AKT_MTOR_SIGNALING-0.350
- MYOGENESIS-0.320
- DNA_REPAIR-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a6136b7b.48bb.4ab0.809d.d89b1cae2837 | — | cohortA1 | 0.811 |
| 2 | TCGA-G2-A2EK-01A-22R-A18C-07 | — | — | 0.808 |
| 3 | SRR8518163 | — | A | 0.804 |
| 4 | MNG622 | — | — | 0.803 |
| 5 | ERR2598080 | fetal | fetal | 0.802 |
| 6 | TCGA-H4-A2HO-01A-11R-A180-07 | — | — | 0.794 |
| 7 | C3N-03210 | — | cohortA1 | 0.793 |
| 8 | C3L-02958 | — | cohortA1 | 0.793 |
| 9 | TCGA-K4-A3WU-01B-11R-A23N-07 | — | — | 0.791 |
| 10 | C3L-03679 | — | cohortA1 | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.050 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |